Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure

Elias Jabbour, Jorge Cortes, Hagop M. Kantarjian, Sergio Giralt, Dan Jones, Roy Jones, Francis Giles, Borje S. Andersson, Richard Champlin, Marcos De Lima

Research output: Contribution to journalArticle

Abstract

Resistance to imatinib mesylate is an emerging problem in the treatment of chronic myeloid leukemia (CML), often associated with point mutations in the Bcr-Abl kinase domain. Outcome of patients with such mutations after allogeneic stem cell transplantation (Allo-SCT) is unknown. Ten imatinib-resistant patients with Bcr-Abl kinase mutations received a transplant: 9 had CML (3 in chronic phase, 4 in accelerated phase, and 2 in blast phase) and 1 had Philadelphia-positive acute lymphocytic leukemia (ALL). Patients harbored 9 different protein kinase mutations (T315I mutation, n = 2). Preparative regimens were ablative (n = 7) and non-ablative (n = 3). All patients engrafted; there were no treatment-related deaths. Disease response was complete molecular (CMR; n = 7), major molecular (n = 2), and no response (n = 1). Three patients (mutations Q252H, E255K, and T315I) died of relapse after Allo-SCT. Seven patients are alive (6 in CMR) for a median of 19 months. Allo-SCT remains an important salvage option for patients who develop resistance to imatinib through Bcr-Abl mutations.

Original languageEnglish (US)
Pages (from-to)1421-1423
Number of pages3
JournalBlood
Volume108
Issue number4
DOIs
StatePublished - Aug 15 2006
Externally publishedYes

Fingerprint

Stem Cell Transplantation
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Stem cells
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Phosphotransferases
Mutation
Salvaging
Transplants
Protein Kinases
Blast Crisis
Imatinib Mesylate
Point Mutation
Recurrence
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. / Jabbour, Elias; Cortes, Jorge; Kantarjian, Hagop M.; Giralt, Sergio; Jones, Dan; Jones, Roy; Giles, Francis; Andersson, Borje S.; Champlin, Richard; De Lima, Marcos.

In: Blood, Vol. 108, No. 4, 15.08.2006, p. 1421-1423.

Research output: Contribution to journalArticle

Jabbour, E, Cortes, J, Kantarjian, HM, Giralt, S, Jones, D, Jones, R, Giles, F, Andersson, BS, Champlin, R & De Lima, M 2006, 'Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure', Blood, vol. 108, no. 4, pp. 1421-1423. https://doi.org/10.1182/blood-2006-02-001933
Jabbour, Elias ; Cortes, Jorge ; Kantarjian, Hagop M. ; Giralt, Sergio ; Jones, Dan ; Jones, Roy ; Giles, Francis ; Andersson, Borje S. ; Champlin, Richard ; De Lima, Marcos. / Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. In: Blood. 2006 ; Vol. 108, No. 4. pp. 1421-1423.
@article{506d90fc9b4549698e990cfda28a1330,
title = "Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure",
abstract = "Resistance to imatinib mesylate is an emerging problem in the treatment of chronic myeloid leukemia (CML), often associated with point mutations in the Bcr-Abl kinase domain. Outcome of patients with such mutations after allogeneic stem cell transplantation (Allo-SCT) is unknown. Ten imatinib-resistant patients with Bcr-Abl kinase mutations received a transplant: 9 had CML (3 in chronic phase, 4 in accelerated phase, and 2 in blast phase) and 1 had Philadelphia-positive acute lymphocytic leukemia (ALL). Patients harbored 9 different protein kinase mutations (T315I mutation, n = 2). Preparative regimens were ablative (n = 7) and non-ablative (n = 3). All patients engrafted; there were no treatment-related deaths. Disease response was complete molecular (CMR; n = 7), major molecular (n = 2), and no response (n = 1). Three patients (mutations Q252H, E255K, and T315I) died of relapse after Allo-SCT. Seven patients are alive (6 in CMR) for a median of 19 months. Allo-SCT remains an important salvage option for patients who develop resistance to imatinib through Bcr-Abl mutations.",
author = "Elias Jabbour and Jorge Cortes and Kantarjian, {Hagop M.} and Sergio Giralt and Dan Jones and Roy Jones and Francis Giles and Andersson, {Borje S.} and Richard Champlin and {De Lima}, Marcos",
year = "2006",
month = "8",
day = "15",
doi = "10.1182/blood-2006-02-001933",
language = "English (US)",
volume = "108",
pages = "1421--1423",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure

AU - Jabbour, Elias

AU - Cortes, Jorge

AU - Kantarjian, Hagop M.

AU - Giralt, Sergio

AU - Jones, Dan

AU - Jones, Roy

AU - Giles, Francis

AU - Andersson, Borje S.

AU - Champlin, Richard

AU - De Lima, Marcos

PY - 2006/8/15

Y1 - 2006/8/15

N2 - Resistance to imatinib mesylate is an emerging problem in the treatment of chronic myeloid leukemia (CML), often associated with point mutations in the Bcr-Abl kinase domain. Outcome of patients with such mutations after allogeneic stem cell transplantation (Allo-SCT) is unknown. Ten imatinib-resistant patients with Bcr-Abl kinase mutations received a transplant: 9 had CML (3 in chronic phase, 4 in accelerated phase, and 2 in blast phase) and 1 had Philadelphia-positive acute lymphocytic leukemia (ALL). Patients harbored 9 different protein kinase mutations (T315I mutation, n = 2). Preparative regimens were ablative (n = 7) and non-ablative (n = 3). All patients engrafted; there were no treatment-related deaths. Disease response was complete molecular (CMR; n = 7), major molecular (n = 2), and no response (n = 1). Three patients (mutations Q252H, E255K, and T315I) died of relapse after Allo-SCT. Seven patients are alive (6 in CMR) for a median of 19 months. Allo-SCT remains an important salvage option for patients who develop resistance to imatinib through Bcr-Abl mutations.

AB - Resistance to imatinib mesylate is an emerging problem in the treatment of chronic myeloid leukemia (CML), often associated with point mutations in the Bcr-Abl kinase domain. Outcome of patients with such mutations after allogeneic stem cell transplantation (Allo-SCT) is unknown. Ten imatinib-resistant patients with Bcr-Abl kinase mutations received a transplant: 9 had CML (3 in chronic phase, 4 in accelerated phase, and 2 in blast phase) and 1 had Philadelphia-positive acute lymphocytic leukemia (ALL). Patients harbored 9 different protein kinase mutations (T315I mutation, n = 2). Preparative regimens were ablative (n = 7) and non-ablative (n = 3). All patients engrafted; there were no treatment-related deaths. Disease response was complete molecular (CMR; n = 7), major molecular (n = 2), and no response (n = 1). Three patients (mutations Q252H, E255K, and T315I) died of relapse after Allo-SCT. Seven patients are alive (6 in CMR) for a median of 19 months. Allo-SCT remains an important salvage option for patients who develop resistance to imatinib through Bcr-Abl mutations.

UR - http://www.scopus.com/inward/record.url?scp=33747156914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747156914&partnerID=8YFLogxK

U2 - 10.1182/blood-2006-02-001933

DO - 10.1182/blood-2006-02-001933

M3 - Article

C2 - 16601247

AN - SCOPUS:33747156914

VL - 108

SP - 1421

EP - 1423

JO - Blood

JF - Blood

SN - 0006-4971

IS - 4

ER -